Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7335 p137
5 February 2005

This article
Reprint   Photocopy

  Acrobat Reader


News summary

Related websites
Shipman Inquiry (more)


GMC review launched in wake of Shipman inquiry

Fifth Shipman report

Fifth Shipman report censured the GMC

The role, structure and function of the General Medical Council, which regulates doctors in the UK, is to be reviewed, Secretary of State for Health John Reid has announced. The move follows criticism and recommendations by the chairman of the Shipman Inquiry, Dame Janet Smith, last year (PJ, 18/25 December 2004, p874).

Dame Janet criticised the GMC for acting in the interests of its registrants rather than putting patient protection first. Her report said that there was a perception that the GMC had a representative role despite the fact that it is solely a regulatory body. She suggested that the GMC cannot rid itself of this perception because of its constitution, which means that it is effectively controlled by elected members.

Dame Janet said: “It is not appropriate that the GMC should be dominated by elected members. It should certainly be dominated by medical members; I am not suggesting that there should be any increase in the proportion of lay members. But I do suggest that there should be more appointed medical members, people who are not beholden to an electorate and who do not see themselves in the position of representatives of the profession.”

Announcing the review, Dr Reid said: “We want to put an end to the idea that the GMC is a representative body for doctors. It is not. Its primary role must be to protect patients.”

The review is to be carried out by Sir Liam Donaldson, the chief medical officer for England. Its three aims will be to identify measures to:

· Strengthen procedures for assuring the safety of patients where a doctor’s performance or conduct poses a risk to patient safety or the effective functioning of services
· Ensure the operation of an effective system of revalidation
· Modify the role, structure and functions of the GMC

Sir Liam will be supported by a 19-member advisory group of representatives of consumer, health care quality and professional interests.

Mandie Lavin, the Royal Pharmaceutical Society’s director of fitness to practise and legal affairs, said: “The Society supports the Government’s review into patient safety and will carefully consider the outcome and recommendations. The Society would wish to contribute to the work of the review and welcomes the comprehensive nature of the membership of the advisory group. Patient safety, public confidence and trust are of paramount importance for all health professionals.”

Society Council member Graham Phillips said that the review is likely to have implications for the Society. He believes that whatever happens to the GMC will happen to the Society.

Mr Phillips said that Council policy is for the Society to have both regulatory and professional representative roles. But he is coming to the view that the Society should divide into separate organisations for the two roles.

“The Government accepts that the Society should be both professional and regulatory, but through the Privy Council it is pushing us in only one direction. Circumstances may force us to a future in which we lose the regulatory role or ask the Government to take regulation away. Council policy is for the Society to have both roles, but I’m close to thinking that it has stopped working for us.”

Back to Top


©The Pharmaceutical Journal